This article is more than 5 years old. Information may no longer be current.
Allergan, Pharmacopeia enter licensing agreement
PRINCETON, N.J. — Allergan has licensed the rights from Pharmacopeia to develop novel compounds that target angiogenesis in ocular diseases, Pharmacopeia announced in a press release.
The agreement resulted in an undisclosed upfront cash payment from Allergan to Pharmacopeia, according to the Princeton-based company. Pharmacopeia has retained the rights to the models in other therapeutic areas. Its compounds “may represent a new means of treating wet age-related macular degeneration, and could represent an important new treatment option for this disease,” the company said in its release.
“We are working with Allergan to investigate alternate mechanistic approaches that could complement or potentially improve upon existing therapies,” said David M. Floyd, MD, chief scientific officer at Pharmacopeia.